Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding its financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the credibility of Tempus AI's joint venture with SoftBank was compromised, suggesting potential "round-tripping" of capital to artificially inflate revenue [3]. - The business model of Ambry Genetics, acquired by Tempus AI, is said to be based on aggressive and potentially unethical billing practices, raising concerns about sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement, indicating operational weaknesses [3]. - These issues collectively reveal vulnerabilities in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Allegations - Following a research report from Spruce Point Capital Management that highlighted numerous concerns regarding Tempus AI's management and financial reporting, the company's stock price fell by over 19% [4]. Group 3: Class Action Process - Investors who purchased Tempus AI common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].

Core Viewpoint - Tempus AI, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed material information during the specified Class Period, which has led to significant investor losses [1][3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Tempus AI securities between August 6, 2024, and May 27, 2025, with a deadline for filing a lead plaintiff motion set for August 12, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation regarding their legal rights and options for recovering losses [2]. Group 2: Allegations Against Tempus AI - The lawsuit alleges that Tempus AI inflated the value of certain contract agreements, many of which involved related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about a joint venture with SoftBank Group Corporation, which allegedly risked credibility by appearing to "round-trip" capital to artificially inflate revenue [3]. - The acquisition of Ambry Genetics Corporation is claimed to have operated under a business model reliant on aggressive and potentially unethical billing practices, exposing it to regulatory and financial risks [3]. - AstraZeneca PLC reportedly reduced its financial support to Tempus AI through a questionable "pass-through payment" structure involving a joint agreement with Pathos AI, Inc. [3]. - These issues are indicative of broader weaknesses in Tempus AI's core operations and long-term revenue outlook [3]. Group 3: Impact on Stock Price - Following the publication of a research report by Spruce Point Capital Management, LLC on May 28, 2025, which highlighted serious concerns regarding Tempus AI's management and operations, the company's stock price fell by over 19% [4].

金融界5月20日消息，上证指数上涨0.38%，中证精选市场生物科技指数 (精选市场生物科技，931669)报 1740.14点。 数据统计显示，中证精选市场生物科技指数近一个月上涨0.54%，近三个月下跌3.50%，年至今上涨 4.24%。 据了解，中证精选市场生物科技指数从全球精选市场选取50只生物科技领域上市公司证券作为指数样 本，反映相应精选市场生物科技领域上市公司证券的整体表现。该指数以2018年12月28日为基日，以 1000.0点为基点。 从指数持仓来看，中证精选市场生物科技指数十大权重分别为：信达生物（13.65%）、百济神州 （12.29%）、Eli Lilly and Co（9.25%）、Johnson & Johnson（7.47%）、Abbvie Inc（6.68%）、Novo Nordisk A/S（4.7%）、Novartis AG（4.6%）、AstraZeneca PLC（4.39%）、Merck & Co Inc （3.97%）、Amgen Inc（3.35%）。 从中证精选市场生物科技指数持仓的市场板块来看，纽约证券交易所占比51.15%、香港证券交易所占 比25.94%、纳 ...

Core Insights - The immunotherapy in oncology market is valued at USD 119.0 billion in 2023 and is projected to grow at a CAGR of 11.6%, reaching USD 319.5 billion by 2032, driven by substantial investments in novel immunotherapies and increased patent filings [1][17]. Market Overview - The patent landscape analysis for immunotherapy in oncology examines the interplay between innovation and industry growth, highlighting patent filing trends and key players [2]. - The report identifies emerging therapeutic targets and assesses the competitive landscape, providing insights into strategic R&D investments [2][3]. Technological Advancements - Innovations in genetic engineering and biotechnology, such as CRISPR and next-generation sequencing, are enhancing the development of novel immunotherapies, leading to a surge in patent filings [10]. - The increasing incidence of cancer globally necessitates the development of new treatments, stimulating research and related patent activities [10]. Market Segmentation - The patent landscape is segmented into four key types: Monoclonal Antibodies, Cytokines and Immunomodulators, Checkpoint Inhibitors, and Others, each representing significant advancements in cancer treatment [6]. - The landscape spans various cancer indications, including lung cancer, colorectal cancer, melanoma, breast cancer, and prostate cancer, reflecting targeted research efforts [7]. Regional Analysis - The United States, Europe, and Asia-Pacific lead in patent filings, with the U.S. dominating due to its robust R&D infrastructure [8]. - Europe, particularly Germany and the UK, contributes significantly through collaborative research and innovation incentives, while the Asia-Pacific region, especially China and Japan, is rapidly emerging due to increasing healthcare investments [8]. Key Players and Patent Profiles - Genentech Inc. is a pioneer in oncology immunotherapy with a focus on monoclonal antibodies and targeted treatments, holding significant patents for drugs like Avastin and Herceptin [11]. - AstraZeneca PLC focuses on immune checkpoint inhibitors, particularly targeting PD-1/PD-L1 pathways, with notable patents for drugs like Imfinzi [12]. - Immatics Biotechnologies GmbH specializes in T-cell receptor therapies, reflecting its focus on novel therapeutic targets [13]. - F. Hoffmann-La Roche AG has a comprehensive patent portfolio covering a broad spectrum of therapies, including immune checkpoint inhibitors [14]. - Incyte Corp is known for its diverse patent portfolio, actively developing small molecule inhibitors and novel immunotherapies [15]. Market Forecast - The estimated market value for immunotherapy in oncology is projected to be USD 132.8 billion in 2024, with a forecasted value of USD 319.5 billion by 2032, indicating robust growth potential [17].